<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211053</url>
  </required_header>
  <id_info>
    <org_study_id>2014-987</org_study_id>
    <nct_id>NCT02211053</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial</brief_title>
  <acronym>ECHOT4</acronym>
  <official_title>Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital du Sacre-Coeur de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital du Sacre-Coeur de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the administration of an infusion of
      levothyroxine can improve heart function in organ donors
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in left ventricular ejection fraction</measure>
    <time_frame>6 hours post infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of cardiac index defined as the difference in cardiac index (L/min)</measure>
    <time_frame>6 hours post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of inotrope and vasopressor doses defined as the difference in mean hour-dose of milrinone, noradrenaline, vasopressin and/or phenylephrine</measure>
    <time_frame>6 hours post infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Converted organs defined as the number of converted hearts according to standard Transplant-Quebec definition and total retrieved organs</measure>
    <time_frame>24 hours post infusion or at the beginning of retrieval surgery, whatever comes first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of de novo atrial fibrillation</measure>
    <time_frame>From beginning of infusion until beginning of retrieval surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of liver recipients</measure>
    <time_frame>6 months post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of thyroid hormones levels</measure>
    <time_frame>Immediately before infusion, 6 hours post infusion and 24 hours post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain Dead Organ Donors</condition>
  <arm_group>
    <arm_group_label>Levothyroxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infusion matched to intervention arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <description>20 mg IV bolus + 10 mg/h infusion</description>
    <arm_group_label>Levothyroxine</arm_group_label>
    <other_name>Synthroid(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior signed written informed from family member

          -  16 years of age or older

          -  Brain death diagnosis

          -  Left ventricular ejection fraction &lt; 50% determined by transthoracic echocardiography
             or hemodynamic instability defined as a mean dose of noradrenaline 0.1 mcg/kg/min +
             vasopressin

        Exclusion Criteria:

          -  Heart failure history

          -  Chronic exogenous oral T4 or T3 before death

          -  Having received T4 infusion before recruitment

          -  Echographic images not interpretable

               -  Age 75 and older

               -  Prior coronary heart disease defined as prior coronary artery bypass graft or
                  percutaneous coronary intervention (with or without stents)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Julie Frenette, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital du Sacre-Coeur de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital du Sacr√©-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Julie Frenette, M.Sc</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2666</phone_ext>
      <email>anne.julie.frenette@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Anne Julie Frenette, M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital du Sacre-Coeur de Montreal</investigator_affiliation>
    <investigator_full_name>Anne Julie Frenette</investigator_full_name>
    <investigator_title>B.Pharm, M.Sc</investigator_title>
  </responsible_party>
  <keyword>Organ donation</keyword>
  <keyword>Brain dead</keyword>
  <keyword>Levothyroxine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

